Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Total Debt (2018 - 2022)

Theravance Biopharma (TBPH) has disclosed Total Debt for 5 consecutive years, with $396.1 million as the latest value for Q2 2022.

  • On a quarterly basis, Total Debt rose 3.69% to $396.1 million in Q2 2022 year-over-year; TTM through Jun 2022 was $396.1 million, a 3.69% increase, with the full-year FY2020 number at $392.2 million, up 71.16% from a year prior.
  • Total Debt was $396.1 million for Q2 2022 at Theravance Biopharma, up from $393.2 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $396.1 million in Q2 2022 to a low of $229.2 million in Q4 2019.
  • A 5-year average of $330.1 million and a median of $378.6 million in 2020 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: dropped 0.17% in 2019, then soared 71.16% in 2020.
  • Theravance Biopharma's Total Debt stood at $229.5 million in 2018, then decreased by 0.17% to $229.2 million in 2019, then skyrocketed by 71.16% to $392.2 million in 2020, then dropped by 1.05% to $388.1 million in 2021, then rose by 2.07% to $396.1 million in 2022.
  • Per Business Quant, the three most recent readings for TBPH's Total Debt are $396.1 million (Q2 2022), $393.2 million (Q1 2022), and $388.1 million (Q3 2021).